Stężenie frakcji kostnej fosfatazy zasadowej (BALP) i zewnątrzkomórkowej domeny receptora HER-2 (ECD/HER-2) w surowicy krwi, podczas leczenia dzieci i młodzieży z mięsakiem kościopochodnym

1Rutkowski P, Warzocha K. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Mięsaki kości, 2013 rok. VM Media Sp z o.o., ISBN 9788375995947.Rutkowski P Warzocha K Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Mięsaki kości 2013 rok. VM Media Sp z o.o., ISBN 9788375995947Search in Google Scholar

2Marais L, Bertie J, Rodseth R, Sartorius B, Ferreira N. Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma 2015;4(3):80-84.Marais L Bertie J Rodseth R Sartorius B Ferreira N Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma 20154380 8410.1016/j.jbo.2015.09.002464899726587373Search in Google Scholar

3Gajewska N, Ambroszkiewicz J, Rychlowska-Pruszynska M, Laskowska-Klita T. Markers of bone formation in children with osteosarcoma. Med. Wieku Rozwoj. 2004;8:235-243.Gajewska N Ambroszkiewicz J Rychlowska-Pruszynska M Laskowska-Klita T Markers of bone formation in children with osteosarcoma. Med Wieku Rozwoj 20048235 243Search in Google Scholar

4Ługowska I, Woźniak W, Ambroszkiewicz J, et al. Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study. Med. Wieku Rozwoj. 2009;13:201-208.Ługowska I Woźniak W Ambroszkiewicz J et al Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study Med. Wieku Rozwoj 200913201 208Search in Google Scholar

5Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev. 2011;12:1717-1722.Limmahakhun S Pothacharoen P Theera-Umpon N et al Relationships between serum biomarker levels and clinical presentation of human osteosarcomas Asian Pac J Cancer Prev 2011121717 1722Search in Google Scholar

6Sternberg RA, Pondenis HC, Yang X, et al. Association between absolute tumor burden and serum bone-specific alkaline phosphatase in canine appendicular osteosarcoma. J Vet Intern Med. 2013;27:955-963.Sternberg RA Pondenis HC Yang X et al Association between absolute tumor burden and serum bone-specific alkaline phosphatase in canine appendicular osteosarcoma J Vet Intern Med 201327955 96310.1111/jvim.1212123734720Search in Google Scholar

7Mohamed A, Krajewski K, Cakar B. Targeted therapy for breast cancer, 2013;183(4):1096-1112.Mohamed A Krajewski K Cakar B Targeted therapy for breast cancer 201318341096 111210.1016/j.ajpath.2013.07.00523988612Search in Google Scholar

8Laudadio J, Quigley D I, Tubbs R., Wolff D J. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007;7(1):53-64.Laudadio J Quigley D I Tubbs R. Wolff D J HER2 testing: a review of detection methodologies and their clinical performance Expert Rev Mol Diagn 20077153 6410.1586/14737159.7.1.5317187484Search in Google Scholar

9Esserman LJ, Moore DH, Tsing P J, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011;129(2):607-616.Esserman LJ Moore DH Tsing P J et al Biologic markers determine both the risk and the timing of recurrence in breast cancer Breast Cancer Res Treat 20111292607 61610.1007/s10549-011-1564-5432475021597921Search in Google Scholar

10Holzer G, Pfandlsteiner T, Koschat M, Noske H, Trieb K, Kotz R. Soluble p185HER-2 in Patients With Malignant Bone Tumours. Pediatric Blood Cancer 2005;44:163-166.Holzer G Pfandlsteiner T Koschat M Noske H Trieb K Kotz R Soluble p185HER-2 in Patients With Malignant Bone Tumours Pediatric Blood Cancer 200544163 16610.1002/pbc.2021715468309Search in Google Scholar

11Ambroszkiewicz J, Gajewska J, Klepacka T, Chełchowska M, Laskowska-Klita T, Woźniak W. A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Polski Merkurisz Lekarski, 2010;29(169):19-26.Ambroszkiewicz J Gajewska J Klepacka T Chełchowska M Laskowska-Klita T Woźniak W A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis Polski Merkurisz Lekarski 20102916919 26Search in Google Scholar

12Liu PP, Leung KS, Kumta SM et al. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology, 1996;53(4):275-280.Liu PP Leung KS Kumta SM et al Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma Oncology 1996534275 28010.1159/0002275738692530Search in Google Scholar

13Zhiping Y, Yanqing H, Guangzhi S et al. Measurement of bone alkaline phosphatase and relative study with osteosarcoma. Front. Med. China, 2007;1(1):54-57.Zhiping Y Yanqing H Guangzhi S et al Measurement of bone alkaline phosphatase and relative study with osteosarcoma Front. Med. China 20071154 5710.1007/s11684-007-0011-924557618Search in Google Scholar

14Levine AM, Triche T, Rosenberg SA. Osteosarcoma cells in tissue culture: Characterisation and localization of alkaline phosphatase activity. Clin. Orthop. Rel. Res., 1980;146:259-268.Levine AM Triche T Rosenberg SA Osteosarcoma cells in tissue culture: Characterisation and localization of alkaline phosphatase activity Clin. Orthop. Rel. Res 1980146259 26810.1097/00003086-198001000-00039Search in Google Scholar

15Lim SM, Kim Y N, Park K H, Kang B, Chon H J, Kim C, Kim J H, Rha S Y. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer. 2016;16:385.Lim SM Kim Y N Park K H Kang B Chon H J Kim C Kim J H Rha S Y Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients BMC Cancer 20161638510.1186/s12885-016-2415-x493272527377907Search in Google Scholar

16Wasilewski-Masker K, Kastle SC, Hudson M M. et al. Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics, 2008;121(3):705-713.Wasilewski-Masker K Kastle SC Hudson M M. et al Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature Pediatrics 20081213705 71310.1542/peds.2007-139618310191Search in Google Scholar

17Dresner-Pollak R, Parker R A, Poku M, Thompson J, Seibel M J, Greenspan S L. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59(5):328-333.Dresner-Pollak R Parker RA Poku M Thompson J Seibel MJ Greenspan SL Biochemical markers of bone turnover reflect femoral bone loss in elderly women Calcif Tissue Int 1996595328 33310.1007/s0022399001358849397Search in Google Scholar

18Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Högler W. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92(2):443-449.Rauchenzauner M Schmid A Heinz-Erian P Kapelari K Falkensammer G Griesmacher A Finkenstedt G Högler W Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years J Clin Endocrinol Metab 2007922443 44910.1210/jc.2006-170617105843Search in Google Scholar

19Bargmann C I, Hung MC, Weinberg R A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319(6050):226-230.Bargmann C I Hung MC Weinberg R A The neu oncogene encodes an epidermal growth factor receptor-related protein Nature 19863196050226 23010.1038/319226a03945311Search in Google Scholar

20Gill J, Gellel D, Gorlick R. HER-2 Involvement in Osteosarcoma. Advances in Experimental Medicine and Biology 2014;804:161-181.Gill J Gellel D Gorlick R HER-2 Involvement in Osteosarcoma Advances in Experimental Medicine and Biology 2014804161 18110.1007/978-3-319-04843-7_924924174Search in Google Scholar